Drozitumab

DB19106InvestigationalProtein Based Therapies

Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by... It was developed by Genentech as a drug for the treatment of cancers.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 10B
Curator reviewed
Also known as: Anti-dr5 rhumab-dr5 · Immunoglobulin g1, anti-(human citokine receptor dr5 (death receptor 5)) (human monoclonal heavy chain), disulfide with human l3-chain, dimer · Rhumab dr5 · Rhumab-dr5 · Usp mab 003, monoclonal igg1
Code names: ANTI-DR5

Resolves to

Compound

UNIISQ67484MA7CAS912628-39-8

Targets

O14763TNFRSF10B

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Drozitumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account